Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL

Inclusion Criteria: * Age≥15 years old * Newly diagnosed B-cell acute lymphoblastic leukemia according to the 2016 WHO classification * The immunophenotype of leukemia cells were CD19 and CD22 positive * Ph- or Ph- like negative * Anticipated survival time more than 12 weeks; * Those who voluntarily participated in this trial and provided informed consent. Exclusion Criteria: * History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular hemorrhagic diseases; * Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past; * Pregnant (or lactating) women; * Patients with severe active infections (excluding simple urinary tract infection and bacterial pharyngitis); * Active infection of hepatitis B virus or hepatitis C virus; * Concurrent therapy with systemic steroids within 2 weeks prior to screening, except for the patients recently or currently receiving inhaled steroids; * Previously treated with any CAR-T cell product or other genetically-modified T cell therapies; * Creatinine\>2.5mg/dl, or ALT / AST \> 3 times of normal amounts, or bilirubin\>2.0 mg/dl; * Other uncontrolled diseases that were not suitable for this trial; * Patients with HIV infection; * Any situations that the investigator believes may increase the risk of patients or interfere with the results of study.